anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Increasing the PPV of monosomy X detected by the non-invasive prenatal test (NIPT) by discriminating a (mosaic) monosomy X genotype of fetal versus maternal origin.
METHODS: Out of 30,700 women referred for NIPT between January 2014 and December 2021, 79 had a high risk result for 45,X. Discrimination between fetal and maternal 45,X was made based on the values for ffX, ffY and SeqFF. Follow-up was provided through analysis of amniotic fluid, maternal blood, umbilical cord blood, neonatal blood and/or placental biopsies.
RESULTS: Follow-up data were available for 70/79 women; after exclusion of one twin pregnancy, 69 pregnancies were evaluated (87.3%). Forty one of those were correctly predicted as being maternal or fetal, for an overall PPV of 59.4% (95% confidence interval [CI] 47%-71%). Of the 33 predicted fetal cases with follow-up, 11 were indeed of fetal origin, equating to a PPV of 33.3% (95% CI 18%-52%); three additional cases turned out to be placental in origin, six were maternal and for 13, no explanation could be found. The PPV of maternal cases was 88.2% (30/34 cases with follow-up correctly predicted; 95% CI 73%-97%). One case turned out to be fetal; for the other three, follow-up studies failed to prove the presence of monosomy X. Two cases for which no prediction on the origin of the monosomy X could be made (inconclusive high-risk NIPT result) turned out to have confined placental mosaicism.
CONCLUSION: Although the PPV for fetal monosomy X remains lower than for the common trisomies, the total PPV for 45,X screening with NIPT can be improved by discerning fetal from (mosaic) maternal 45,X genotype. Thorough follow-up to determine the origin of the aberrant NIPT result is advised, so that women can be adequately counseled on the risk in their current and future pregnancies and, in case of maternal mosaic monosomy X, of their own prospects.
BACKGROUND: Early blight and brown leaf spot are often cited as the most problematic pathogens of tomato in many agricultural regions. Their causal agents are Alternaria spp., a genus of Ascomycota containing numerous necrotrophic pathogens. Breeding programs have yielded quantitatively resistant commercial cultivars, but fungicide application remains necessary to mitigate the yield losses. A major hindrance to resistance breeding is the complexity of the genetic determinants of resistance and susceptibility. In the absence of sufficiently resistant germplasm, we sequenced the transcriptomes of Heinz 1706 tomatoes treated with strongly virulent and weakly virulent isolates of Alternaria spp. 3 h post infection. We expanded existing functional gene annotations in tomato and using network statistics, we analyzed the transcriptional modules associated with defense and susceptibility.
RESULTS: The induced responses are very distinct. The weakly virulent isolate induced a defense response of calcium-signaling, hormone responses, and transcription factors. These defense-associated processes were found in a single transcriptional module alongside secondary metabolite biosynthesis genes, and other defense responses. Co-expression and gene regulatory networks independently predicted several D clade ethylene response factors to be early regulators of the defense transcriptional module, as well as other transcription factors both known and novel in pathogen defense, including several JA-associated genes. In contrast, the strongly virulent isolate elicited a much weaker response, and a separate transcriptional module bereft of hormone signaling.
CONCLUSIONS: Our findings have predicted major defense regulators and several targets for downstream functional analyses. Combined with our improved gene functional annotation, they suggest that defense is achieved through induction of Alternaria-specific immune pathways, and susceptibility is mediated by modulating hormone responses. The implication of multiple specific clade D ethylene response factors and upregulation of JA-associated genes suggests that host defense in this pathosystem involves ethylene response factors to modulate jasmonic acid signaling.
INTRODUCTION: In pre-hospital settings, identifying a deteriorating child can be challenging, especially considering that the proportion of paediatric patients with acute illnesses is lower compared with adults. This challenge is exacerbated in pre-hospital settings, where information might be scarce. Physiological alterations indicating changes in a patient's condition can be detected hours preceding a cardiac arrest. Therefore, maintaining continuous monitoring of the patient's clinical condition is crucial to detecting any physiological changes promptly, facilitating early identification of critical illness. This scoping review aims to assess the extent, range and nature of published research related to recognising paediatric out-of-hospital clinical deterioration by pre-hospital staff.
METHODS AND ANALYSIS: This scoping review is registered with the Open Science Framework. The review will follow the Joanna Briggs Institute's (JBI) methodology for scoping reviews. A systematic search of relevant databases (MEDLINE, EMBASE, Web of Science, CINAHL and Scopus) will be conducted. In this scoping review, all types of study designs including quantitative and qualitative studies will be considered. The inclusion is limited to English-language studies published between January 1990 and March 2024. Two independent reviewers (AG and SS) will conduct a thorough screening of titles and abstracts against the pre-defined inclusion criteria for the review. For the selected citations, the full texts will undergo detailed assessment by the two reviewers, ensuring alignment with the inclusion criteria. A quality assessment of the included studies will be done using the Mixed Methods Appraisal Tool. The findings will be presented using diagrams or tables, supplemented by narrative summaries following the JBI guidelines.
ETHICS AND DISSEMINATION: Ethical approval is not required. The findings will be disseminated through publication in a peer-reviewed journal and presentation at conferences and/or seminars.
Systems and methods are described herein for processing electronic medical images. For example, one or more digital medical images of at least one pathology specimen, the pathology specimen being associated with a patient may be received. Additionally, an external designation of the one or more digital medical images may be received. The one or more digital medical images may be provided to one or more machine learning systems, the one or more machine learning systems each having been trained to analyze medical images using one of a plurality of versions of a protocol. The one or more machine learning systems, may determine machine learning system designations for the one or more digital medical images. The external designation may be compared to the machine learning system designations and, based on the comparison, determining whether the external designation matches a predetermined protocol.
Concurrent Chemoradiotherapy followed by 3 cycles adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday.
The design of a clinical trial for a rare disease can be challenging. An optimal study design is required to effectively study the clinical outcomes for possible therapies for these types of disorders. Understanding the study participants' experiences as well as barriers and facilitators of participation are important to optimize future research and to inform clinical trial management. Centronuclear myopathies (CNMs) including X-linked myotubular myopathy (XLMTM) are a group of rare congenital myopathies for which there is no cure currently. Since 2014, a number of natural history studies and clinical trials have been conducted in CNMs. Two trials have been prematurely terminated because of severe adverse events. Since no research has been conducted regarding trial experience in CNM, we performed a scoping literature research on clinical trial experience of patients with neuromuscular disorders in general. The most common barriers to trial participation of patients comprise concerns about potential harmful effects, opportunity loss and the expected burden on daily life. The most common facilitators were an expected benefit on the disease course, altruism and collateral benefit. While several results are in line with trial experiences of other types of patients, for example oncological patients, distinctions can be made for patients with CNM and other neuromuscular disorders. However, the limited availability of relevant literature suggests that future (qualitative) research should focus on trial experiences in CNM patients.
NEW MATERIAL:Non A, Non B hepatitis virus antigen peptides containing an amino acid sequence of the formula or a part thereof. USE:A diagnostics or a remedy for non A, non B hepatitis. PREPARATION:For example, plasma of a patient of non A, non B hepatitis is concentrated and the whole nucleic acids in the plasma are separated using the guanidinium thiocyanate method. The separated nucleic acids are treated with DNase to decompose human-derived DNA and RNA is separated. cDNA is synthesized using the separated RNA as a template and cDNA library is formed thereby. The resultant cDNA library is subsequently screened using a prove to select a positive clone containing cDNA capable of coding the non A, non B hepatitis virus antigen peptide and DNA is extracted therefrom. The extracted DNA is treated with a restriction enzyme, then combined with a manifestation vector and introduced into a host for transformation thereof. The obtained transformant is cultured, thus obtaining the objective antigen peptide of the formula.
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for the treatment of cerebral infarction, administrable even to a patient after cerebral infarction acute stage passage.  <P>SOLUTION: The therapeutic pharmaceutical composition for the treatment of cerebral infarction comprises a thrombolytic agent and a binding inhibitor for inhibiting the binding of a vascular endothelial growth factor (VEGF) to a receptor of VEGF. The therapeutic pharmaceutical composition for the treatment of cerebral infarction is, if necessary, administered to patients after cerebral infarction acute stage passage. The therapeutic pharmaceutical composition for the treatment of cerebral infarction, if necessary, contains tissue type plasminogen-activator (t-PA) or its derivative. The therapeutic pharmaceutical composition for the treatment of cerebral infarction, if necessary, contains an anti-VEGF-A neutralizing antibody or a derivative thereof.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Investigational drug(=Leuplin Inj.)is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
Men between the ages of 45-74 when they received a decision aid for prostate cancer screening with no prior diagnosis of prostate cancer. These people will see items only pertaining to prostate cancer screening.
PROBLEM TO BE SOLVED: To solubilize a protein antigen produced in a culture medium for a bacterium of the genus Bordetella without causing a loss thereof and readily carry out the purification of a pertussis toxin by using a specific buffer solution containing a surfactant added thereto. SOLUTION: A protein antigen produced in a culture medium for a bacterium of the genus Bordetella in the form of a precipitate or a freeze-dried product is solubilized in a carbonate buffer solution at pH 8.3-11.6 containing a surfactant [e.g. sorbitan polyoxyethylene (20) monooleate] in an amount of <1 wt.% added thereto. The carbonate buffer solution can be prepared by dissolving a mixture of, e.g. sodium or potassium bicarbonate with sodium or potassium carbonate in water. The molar concentration of the carbonate buffer solution is preferably 0.025-0.5 M. For example, Bordetella pertussis and Bordetella bronchiseptica are cited as the bacterium of the genus Bordetella.
Intron retention is a mechanism of post-transcriptional gene regulation, including genes involved in erythropoiesis. Erythropoietin (EPO) is a hormone without evidence of intracellular vesicle storage that regulates erythropoiesis. We hypothesize that EPO uses intron retention as a mechanism of post-transcriptional regulation in response to hypoxia and ischemia. Cell models of hypoxia and ischemia for kidney, liver, and brain cells were examined for intron retention by real time quantitative PCR. EPO expression increased in most cells except for blood brain barrier and liver cells. The intron retained transcript ratio decreased in brain cells, except for Astrocytes, but showed no change in kidney or liver after 24 h of ischemia. The shift in intron ratio was maintained when using poly (A) enriched cDNA, suggesting that intron retention is not due to immature transcripts. The expression of EPO was elevated at variable time points amongst cell models with the intron ratio also changing over a time course of 2 to 16 h after ischemia. We conclude that intron retention is a mechanism regulating EPO expression in response to ischemia in a tissue specific manner.
BACKGROUND: Methotrexate is an essential medicine used to treat childhood malignancies including acute lymphoblastic leukemia. Neurotoxicity manifesting as leukoencephalopathy is an important adverse effect of methotrexate. Methotrexate-induced leukoencephalopathy classically demonstrates sub-acute-onset neurological manifestations that include learning disability, progressive dementia, drowsiness, seizures, ataxia, and hemiparesis. These are rare in children and are generally reported following intrathecal or intravenous use of methotrexate. In contrast, acute onset neurotoxicity with oral use of methotrexate is very rare. We report a 10-year-old boy presenting with acute onset limb weakness and neurological signs due to methotrexate-induced leukoencephalopathy following oral methotrexate.
CASE PRESENTATION: A 10-year-old Sri Lankan boy presented with fever and headache for 5 days and difficulty in walking for 2 days. He was unable to stand unaided on admission, and his parents complained of repetitive, involuntary extension movements involving the right upper limb. He is a child diagnosed with acute lymphoblastic leukemia who was on treatment for a relapse with daily oral dexamethasone and mercaptopurine, weekly oral methotrexate and folinic acid, and once every two weeks intrathecal vincristine. On examination, he had dystonic movements of the right upper limb and hypotonia and reduced muscle power (grade 3/5) of the left upper and lower limbs proximally and distally. The muscle power of the right side was grade 4 (out of 5). Tendon reflexes were diminished in all four limbs, and the plantar response was flexor bilaterally. The child had dysmetria and intension tremors on both sides. T2-weighted magnetic resonance imaging of the brain revealed symmetrical high signal intensities with diffusion restriction involving bilateral putamen, subcortical areas, and deep white matter, suggesting treatment-related neurotoxicity due to methotrexate-induced leukoencephalopathy. Oral methotrexate was discontinued. He showed gradual improvement in limb weakness and other neurological signs following treatment with intravenous folinic acid, aminophylline, dexamethasone, and oral dextromethorphan.
CONCLUSION: This case report describes a patient with rapidly progressing methotrexate-induced leukoencephalopathy following oral methotrexate. It highlights that the risk of neurotoxicity persists even with the oral use of methotrexate; therefore, the prescribers should be vigilant of this uncommon side effect.
According to one embodiment, a method, computer system, and computer program product for biomarker prioritization is provided. The embodiment may include collecting data from a medical device associated with a user. The embodiment may also include identifying, for each type of data, at least one biomarker generated by the medical device associated with the user. The embodiment may further include associating each biomarker with a concerned component and/or a medical model. The embodiment may also include assigning a biomarker priority to a related component. The embodiment may further include generating a schedule for resource processing based on the biomarker priority. The embodiment may also include executing the schedule for resource processing.
BACKGROUND: Child growth influences future health and learning. School readiness refers to a child's ability to meet developmental expectations at school entry. The association of early growth rate and patterns with school readiness remains unknown.
OBJECTIVE: To determine the association of child body mass index (BMI) growth with school readiness in a cohort of young children.
METHODS: A prospective cohort study (2015-2022) was conducted in children 0-6 years enrolled in the TARGet Kids! research network in Toronto, Canada. Two analytical approaches were used to measure growth using child weight and height/length data between 0 and 4 years: (i) age- and sex-standardised BMI (zBMI) growth rate per year using a piecewise linear model; and (ii) distinct zBMI trajectories using latent class mixed models. School readiness (4-6 years) was measured using teacher-completed Early Development Instrument (EDI). Robust Poisson models and marginal linear models using generalised estimating equations were used adjusting for confounders identified a priori.
RESULTS: In this study of 1077 children (mean age at EDI completion: 4.8 years; 52.6% male) with 6415 zBMI measurements, mean growth rate was 0.65 zBMI units/year (0-2 years) and -0.11 zBMI units/year (2-4 years). Two distinct zBMI trajectories were identified: the stable trajectory and the catch-up trajectory. There was insufficient evidence that zBMI growth rates (risk ratio 1.10, 95% confidence interval 0.78, 1.55 for 0-2 years; risk ratio 0.71, 95% confidence interval 0.32, 1.57 for 2-4 years) or trajectories (risk ratio 1.05, 95% confidence interval 0.82, 1.35, catch-up trajectory vs. stable trajectory) were associated with school readiness.
CONCLUSIONS: No association was found between BMI growth and school readiness. School readiness may be more impacted by factors directly related to obesity or adiposity at the time of EDI measurement rather than growth.
After single doses of 10 to 40 mg of fosinopril, serum ACE activity was inhibited by at least 90% from 2 to 12 hours after dosing. At 24 hours, serum ACE activity remains suppressed by 85 to 93%.

Administration of fosinopril to patients with mild to moderate hypertension results in a reduction of both supine and standing blood pressure to about the same extent with no compensatory tachycardia. In studies in hypertensive patients after three months of fosinopril monotherapy, hemodynamic responses to various stimuli (isometric exercise, 45° head-up tilt, mental challenges) were unchanged compared to baseline, suggesting that fosinopril did not affect the activity of the sympathetic nervous system. Instead, fosinopril-induced reduction in blood pressure appears to be mediated by a reduction in peripheral vascular resistance without reflex cardiac effects. In similar studies, renal, splanchnic, cerebral, and skeletal-muscle blood flows were all unchanged compared to baseline, as was glomerular filtration rate. Symptomatic postural hypotension is infrequent, although it can occur in patients who are salt- and/or volume-depleted (see WARNINGS).

Following oral administration of single doses of 10 to 40 mg, fosinopril lowered blood pressure within one hour, with peak reductions achieved 2 to 6 hours after dosing. The antihypertensive effect of a single dose persisted for 24 hours. Following four weeks of monotherapy in placebo-controlled trials in patients with mild to moderate hypertension, once-daily doses of 20 to 80 mg lowered supine or seated blood pressures (systolic/diastolic) 24 hours after dosing by an average of 8 to 9/6 to 7 mmHg more than placebo. The trough effect was about 50 to 60% of the peak diastolic response and about 80% of the peak systolic response.

In clinical studies of various combinations that included 0 to 40 mg of fosinopril and 0 to 37.5 mg of hydrochlorothiazide, the antihypertensive effects were increased with increasing dose of either component. Peak blood pressure reductions were achieved 2 to 6 hours after dosing. The mean reductions in seated blood pressure (systolic/diastolic) associated with fosinopril sodium and hydrochlorothiazide tablets 10/12.5 after 24 hours were 9 to 18/5 to 7 mmHg greater than those associated with placebo; those associated with fosinopril sodium and hydrochlorothiazide tablets 20/12.5 after 24 hours were 12 to 17/8 to 10 mmHg greater than those associated with placebo. These trough effects were 60 to 90% of the corresponding peak effects.

Although hydrochlorothiazide tends to be more effective in low-renin hypertensive patients (mainly blacks), and fosinopril—like other ACE inhibitors—tends to be more effective in high-renin patients (mainly non-blacks), the effectiveness of fosinopril sodium and hydrochlorothiazide is independent of race, age, and gender.
<P>PROBLEM TO BE SOLVED: To easily input prescription contents for medical administrative work in a device for inputting the prescription contents.  <P>SOLUTION: An input processing part of prescription contents 120 in a CPU 102 of a device for inputting prescription contents 100 has a function for inputting the prescription contents for the administrative work. The contents of the previous prescriptions are stored into a prescription data storage device 108 as a prescription database. When acquiring abbreviated expressions indicating names of a patient and a medical institute and the prescription contents from an input unit 104, the database is retrieved by using the expressions as a retrieval key, and previous prescriptions which are issued from an identical medical institute regarding the patient and have the prescription contents in a range recognized by the expressions are narrowed down and extracted. The previous prescription matching with the prescription to be a subject for inputting the prescription contents is selected among the extracted prescriptions, and the contents are copied as they are to be determined as the prescription contents of this time.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The invention belongs to the field of enzymology and pharmaceutical chemistry, and relates to Bacillus spp and hyaluronidase and preparation method and purpose thereof. Concretely, the invention relates to Bacillus spp, and the preservation number is CGMCC No. 5744, and the preservation date is February 8, 2012, and the preservation unit is China General Microbiological Culture Collection Center (CGMCC). The invention also relates to a hyaluronidase and preparation method thereof, and purposes of hyaluronidase in preparing oligomeric hyaluronic acid or salts thereof or low molecular hyaluronic acid or salts thereof. The preparation of oligomeric hyaluronic acid or salts thereof or low molecular hyaluronic acid or salts thereof by using hyaluronidase of the present invention has the advantages of simple operation, mild condition, non-destroy of the product structure and low cost. The product is suitable for large scale industrialized production. The oligomeric hyaluronate prepared by the invention has the advantages of good transdermal absorbency, good purity, non-cytotoxicity, good antioxidation, etc., and can be used in the fields of cosmetic, foodstuff and medicine.